Skip to main content
. 2017 Jan 20;7:40961. doi: 10.1038/srep40961

Figure 1. Nesfatin-1 attenuated MPTP-induced depletion of DA and its metabolites in the striatum (n = 6).

Figure 1

(A) Striatal DA levels in control mice, mice treated with MPTP alone, and mice treated with MPTP+nesfatin-1 (100 ng, 200 ng, and 400 ng/mouse). (B) Striatal HVA levels in the different groups. (C) Striatal DOPAC levels in the different groups. Each value represents the mean ± SEM. (D) The effects of nesfatin-1 on the number of TH-immunoreactive fibers in the striatum. (a) Control treatment, (b) MPTP alone, (c) MPTP+nesfatin-1 (100 ng/mouse), (d) MPTP+nesfatin-1 (200 ng/mouse), and (e) MPTP+nesfatin-1 (400 ng/mouse). *P < 0.01, compared with the control group. #P < 0.05, compared with the MPTP group. (DOPAC: dihydroxyphenylacetic acid, HVA: homovanillic acid, MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Str: Striatum, TH: tyrosine hydroxylase).

HHS Vulnerability Disclosure